{"id":"5-fluorouracil-leucovorin-panitumumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Skin rash (panitumumab-related)"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"5-fluorouracil (5-FU) is a pyrimidine antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. Leucovorin (folinic acid) enhances 5-FU efficacy by stabilizing the 5-FU–thymidylate synthase complex. Panitumumab is a fully human monoclonal antibody targeting epidermal growth factor receptor (EGFR), blocking ligand-induced receptor activation and downstream proliferation signaling. Together, these agents provide dual mechanisms targeting DNA synthesis and growth factor signaling in colorectal cancer cells.","oneSentence":"This combination uses 5-fluorouracil and leucovorin as chemotherapy agents to inhibit thymidylate synthase and enhance fluorouracil cytotoxicity, while panitumumab blocks EGFR signaling to prevent tumor cell growth and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:26:40.390Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (Phase 2 investigation)"}]},"trialDetails":[{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":94},{"nctId":"NCT06252649","phase":"PHASE3","title":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-07-17","conditions":"Metastatic Colorectal Cancer","enrollment":450},{"nctId":"NCT06820463","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-24","conditions":"Metastatic Colorectal Cancer","enrollment":390},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT06268015","phase":"PHASE2","title":"Botensilimab and Balstilimab Optimization in Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nicholas DeVito, MD","startDate":"2024-11-18","conditions":"Colorectal Cancer","enrollment":16},{"nctId":"NCT03366155","phase":"PHASE2","title":"Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-24","conditions":"Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma","enrollment":24},{"nctId":"NCT05030493","phase":"","title":"An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2021-08-31","conditions":"Colorectal Cancer","enrollment":787},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT06967155","phase":"PHASE2","title":"A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-03-01","conditions":"Neoplasms","enrollment":23},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT07124884","phase":"PHASE2","title":"5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-08-31","conditions":"Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer","enrollment":300},{"nctId":"NCT02885753","phase":"PHASE3","title":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-12","conditions":"Colorectal Neoplasms","enrollment":348},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT06978400","phase":"PHASE2","title":"A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-03-01","conditions":"Neoplasms","enrollment":64},{"nctId":"NCT02394834","phase":"","title":"An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2015-05-29","conditions":"Colorectal Cancer","enrollment":757},{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673},{"nctId":"NCT02980510","phase":"PHASE2","title":"Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2016-12","conditions":"Metastatic Colorectal Cancer","enrollment":219},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT01814501","phase":"PHASE2","title":"Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab","status":"COMPLETED","sponsor":"John Hays","startDate":"2013-02-01","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":16},{"nctId":"NCT03635021","phase":"PHASE3","title":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2018-10-15","conditions":"Colorectal Cancer","enrollment":419},{"nctId":"NCT03164655","phase":"PHASE2","title":"Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-07-25","conditions":"Colorectal Cancer Metastatic","enrollment":20},{"nctId":"NCT06509126","phase":"PHASE3","title":"Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2024-06-12","conditions":"Colorectal Cancer Stage IV","enrollment":500},{"nctId":"NCT02394795","phase":"PHASE3","title":"Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-05-29","conditions":"Colorectal Cancer","enrollment":823},{"nctId":"NCT01307956","phase":"PHASE2","title":"Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2011-02-28","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Stage IIA Esophageal Cancer","enrollment":11},{"nctId":"NCT01328171","phase":"PHASE2","title":"FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2011-04","conditions":"Metastatic Colorectal Cancer","enrollment":93},{"nctId":"NCT01991873","phase":"PHASE2","title":"Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-04","conditions":"Metastatic Colorectal Cancer","enrollment":387},{"nctId":"NCT03231722","phase":"PHASE3","title":"First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2017-09-13","conditions":"Metastatic Colorectal Cancer","enrollment":435},{"nctId":"NCT00819780","phase":"PHASE2","title":"PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-04-24","conditions":"Colon Cancer, Colorectal Cancer, Rectal Cancer","enrollment":285},{"nctId":"NCT00364013","phase":"PHASE3","title":"PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-08-01","conditions":"Metastatic Colorectal Cancer","enrollment":1183},{"nctId":"NCT00339183","phase":"PHASE3","title":"Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-06-30","conditions":"Metastatic Colorectal Cancer","enrollment":1186},{"nctId":"NCT03940131","phase":"PHASE2","title":"Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR","status":"UNKNOWN","sponsor":"King Abdullah Medical City","startDate":"2020-06-10","conditions":"Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT03000374","phase":"PHASE2","title":"Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery","status":"COMPLETED","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2017-05-30","conditions":"Rectal Cancer","enrollment":34},{"nctId":"NCT03751176","phase":"PHASE2","title":"Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal","status":"UNKNOWN","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2018-11-08","conditions":"Colorectal Cancer Metastatic","enrollment":31},{"nctId":"NCT03142516","phase":"PHASE2","title":"FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status","status":"COMPLETED","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2017-10-31","conditions":"Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Cancer Metastatic","enrollment":20},{"nctId":"NCT03311750","phase":"PHASE2","title":"Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2018-03-26","conditions":"Advanced Colorectal Cancer","enrollment":23},{"nctId":"NCT02448810","phase":"PHASE2","title":"Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Baxalta now part of Shire","startDate":"2015-06-15","conditions":"Metastatic Colorectal Cancer","enrollment":115},{"nctId":"NCT03300609","phase":"PHASE3","title":"5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2018-02-27","conditions":"Colorectal Adenocarcinoma, RAS Wild Type, Stage III Colorectal Cancer AJCC v7","enrollment":4},{"nctId":"NCT02904031","phase":"PHASE2","title":"Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2016-07","conditions":"Elderly Metastatic Colorectal Cancer Patients","enrollment":180},{"nctId":"NCT00508404","phase":"PHASE2","title":"Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-05-09","conditions":"Metastatic Colorectal Cancer","enrollment":154},{"nctId":"NCT02337946","phase":"PHASE2","title":"Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-10-16","conditions":"Colorectal Carcinoma","enrollment":164},{"nctId":"NCT04034173","phase":"PHASE2","title":"Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation","status":"NOT_YET_RECRUITING","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2019-08-01","conditions":"Treatment Related Cancer","enrollment":120},{"nctId":"NCT03069950","phase":"PHASE2","title":"Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-28","conditions":"Colorectal Adenocarcinoma Metastatic to the Liver","enrollment":""},{"nctId":"NCT01260415","phase":"PHASE2","title":"A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-08","conditions":"Colorectal Cancer, Liver Metastases","enrollment":11},{"nctId":"NCT00115765","phase":"PHASE3","title":"PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-06-01","conditions":"Colorectal Cancer","enrollment":1053},{"nctId":"NCT00418938","phase":"PHASE2","title":"SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-11-01","conditions":"Cancer, Colon Cancer, Colorectal Cancer","enrollment":266},{"nctId":"NCT02508077","phase":"PHASE2","title":"FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2016-02-16","conditions":"Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer","enrollment":1},{"nctId":"NCT00885885","phase":"PHASE2","title":"Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2009-05","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT01704703","phase":"PHASE2","title":"Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2012-10","conditions":"Stage IV Colorectal Cancer","enrollment":72},{"nctId":"NCT01895257","phase":"PHASE3","title":"Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer","status":"UNKNOWN","sponsor":"Universiteit Antwerpen","startDate":"2013-08","conditions":"Colorectal Cancer","enrollment":162},{"nctId":"NCT00610948","phase":"PHASE1","title":"Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2008-03","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":74},{"nctId":"NCT01508000","phase":"PHASE2","title":"Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2013-06","conditions":"Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer","enrollment":44},{"nctId":"NCT02476045","phase":"PHASE2","title":"Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2015-06","conditions":"Metastatic Colorectal Cancer","enrollment":224},{"nctId":"NCT00332163","phase":"PHASE2","title":"Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04","conditions":"Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities","enrollment":95},{"nctId":"NCT00411450","phase":"PHASE2","title":"Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-11","conditions":"Colon Cancer, Colorectal Cancer, Rectal Cancer","enrollment":116},{"nctId":"NCT01226719","phase":"PHASE2","title":"FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2010-12","conditions":"Colorectal Cancer","enrollment":15},{"nctId":"NCT00111761","phase":"PHASE2","title":"Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-07","conditions":"Colorectal Cancer","enrollment":43},{"nctId":"NCT00101894","phase":"PHASE1","title":"Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-12","conditions":"Rectal Cancer, Colon Cancer","enrollment":119}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"5-fluorouracil,leucovorin,panitumumab","genericName":"5-fluorouracil,leucovorin,panitumumab","companyName":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","companyId":"fondazione-irccs-istituto-nazionale-dei-tumori-milano","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses 5-fluorouracil and leucovorin as chemotherapy agents to inhibit thymidylate synthase and enhance fluorouracil cytotoxicity, while panitumumab blocks EGFR signaling to prevent tumor cell growth and survival. Used for Metastatic colorectal cancer (Phase 2 investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}